Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Our BioTherapeutics Leadership

Janssen BioTherapeutics Leadership




Retina image

Sanjaya Singh, Ph.D., is Global Head, Janssen BioTherapeutics within Janssen Research & Development. Sanjaya is responsible for leading an organization focused on biotherapeutic research, discovery, toxicology, clinical pharmacology and strategic external collaboration. In this role, Sanjaya drives the strategy and overall vision to expand and apply the capabilities of Janssen Research & Development to the discovery and development of protein, peptide and cell-based therapeutics.

Sanjaya is an accomplished scientific and business leader with more than 25 years of industry and academic experience. Prior to joining Johnson & Johnson, Sanjaya spent nine years at Boehringer Ingelheim, most recently serving as Vice President, Biotherapeutics Discovery. During his tenure, Sanjaya led a global team responsible for building a competitive and productive pre-clinical and clinical biotherapeutics pipeline. He has successfully led the identification of therapeutic targets in the field of immunomodulation and has developed biologic molecules in the fields of immunology, oncology, ophthalmology, cardio-metabolic and infectious disease.

In the realm of academia, Sanjaya held a faculty position in the Department of Molecular Biology at the Institute of Life Sciences in India. An author of numerous peer-reviewed articles, Sanjaya also is co-author on more than 25 patents.

Sanjaya earned a Ph.D. in Molecular Biology from Banaras Hindu University, Varanasi, Uttar Pradesh, India. He served as a Postdoctoral Fellow in the Department of Molecular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, and as a Research Associate in the Department of Biochemistry and Molecular Biology, also at MD Anderson Cancer Center in Texas.

Sanjaya Singh, Ph.D.

Global Head, Janssen BioTherapeutics

Barry Springer, Ph.D., is Vice President, External Innovation & Strategy for Janssen Biotherapeutics. Barry is responsible for driving the coordination of strategic initiatives for the organization and leading scientific business partnering efforts. He helps to forge internal and external collaborations, including more robust interactions among large and small molecule research activities and technology platforms. In his 10+ years within Janssen, Barry has helped identify and establish strategic external partnerships for pharmaceutical and biologics discovery research.

With more than 23 years of experience in drug discovery and development, Barry’s expertise spans both small and large molecule discovery and development. Prior to joining the Janssen Pharmaceutical Companies of Johnson & Johnson, Barry spent seven years with 3-Dimensional Pharmaceuticals in multiple roles, most recently as Executive Director of Macromolecular Sciences at the time of the organization’s acquisition by Johnson & Johnson. In this role, Barry was responsible for all drug discovery-enabling platforms and protein engineering, expression, purification and structural biology teams and programs, as well as the company’s integration into the Johnson & Johnson organization.

Barry has authored a number of publications in scientific journals and participated in numerous invited lectures. He has also been awarded multiple patents as well as National Institutes of Health and National Institutes of Standards and Technology research grants for his work in the field of biotechnology.

Barry earned a B.S. in Microbiology, an M.S. in Biology, and Ph.D. in Biochemistry, all from the University of Illinois. Barry was also a postdoctoral fellow in the Department of Chemistry at the University of California.

Barry Springer, Ph.D.


Gopi Shankar,  Ph.D., MBA, FAAPS, is Vice President and Head of Biologics Development Sciences (BDS) for Janssen BioTherapeutics (JBIO)

In this role, he is responsible for leading more than 135 employees and 30 sponsored partners/flex staff who contribute to scientific and operational deliverables across the functional areas of biophysics, translational pharmacology & model-guided drug design, and bioanalytical sciences (Pharmacokinetics [PK], Immunogenicity and Target Engagement). The BDS department drives the development of biologic therapeutics discovered by JBIO as well as in-licensed or acquired assets. 

After a brief post-doctoral tenure, he managed Quality Control & Immune Monitoring at Northwest Biotherapeutics (Seattle, WA) from 1999 to 2002. In 2003 Gopi joined Centocor, as a Senior Research Scientist overseeing clinical immunogenicity. Subsequently he assumed progressively greater responsibilities over immunogenicity and the Bioanalytical Laboratory, supporting all biologics development at Janssen R&D, from preclinical through post-market studies.

A world-renowned expert in the field of immunogenicity, Gopi has published in the areas of basic immunological research and technical, strategic and regulatory best practices. He is a prominent leader at the American Association of Pharmaceutical Scientists (AAPS) and has led or contributed to several highly cited articles on immunogenicity, including six industry whitepapers and a chapter in the United States Pharmacopeia. 

During his 18-year professional career, Gopi has focused on the development of innovative solutions to scientific hurdles, developed consensus and harmonized scientific practices, many of which have been adopted by regulatory agencies in their public scientific guidance documents. These approaches include anti-drug antibody detection methods development and validation, resolution of assay interferences to improve accuracy, and the establishment of terminology and analytical approaches for clinical immunogenicity.

His research, consensus-building efforts and best-practice publications, both independently and via AAPS, have transformed the thinking and tactical processes related to immunogenicity around the globe. For his contributions to pharmaceutical science, AAPS conferred Fellow status to him in 2015.

Gopi earned an M.S. in Molecular Biology from Oklahoma State University, a Ph.D. in Immunology from University of Kentucky, a Certificate in Biomedical Regulatory Affairs from the University of Washington, and an Master’s in Business Administration in Leadership and General Management from Drexel University in Philadelphia, Pennsylvania. Gopi is based in Spring House, Pennsylvania, and is a member of the JBIO Leadership Team.

Gopi Shankar, Ph.D.

Vice President and Head,
Biologics Development Sciences
Janssen BioTherapeutics